Exelixis, Inc.: Expansion Of Cabometyx, Pipeline Development & Future Therapeutic Candidates! 

Exelixis, Inc. presented its second-quarter 2024 financial results, revealing a period of strong performance and
strategic advancements in its portfolio. The company highlighted significant growth in both its top and bottom
lines, primarily driven by the success of the cabozantinib franchise, demonstrating a robust market presence,
especially in renal cell carcinoma (RCC). Globally, net product revenues from the cabozantinib franchise, along
with revenues from partnerships, showed significant increases, totaling $618 million for the quarter. This growth
is further emphasized by a $150 million milestone payment from Ipsen, showcasing the international strength of
the franchise.